Below are articles from various sources about members of MCB and their research.
"The European Patent Office (EPO) has announced its intention to grant a broad patent for the revolutionary CRISPR-Cas9 gene-editing technology to the University of California, the University of Vienna and Emmanuelle Charpentier."
MCB Professors Russell Vance and Matt Welch were among the 73 new ASM fellows. "Fellows of the American Academy of Microbiology, an honorific leadership group within the ASM, are elected annually through a highly selective, peer-review process, based on their records of scientific achievement and original contributions that have advanced microbiology."
A study co-authored by MCB and Chemistry Professors Jamie Cate and Jennifer Doudna found a new method to selectively target disease-bearing proteins without damaging the cells containing them. This technology could lead to an alternative to antibiotic treatments, and could have implications for treating cancer and neurological diseases.
MCB Associate Professor of Cell and Developmental Biology Diana Bautista has been appointed to the "Class of 1943 Memorial Chair." The endowed chair is rotated among disciplines and departments at the discretion of the Chancellor.
An alumnus of the MCB Community returns -- Dr. Marion Nestle, (who received her PhD in Molecular Biology from UC Berkeley in '68) will present the Weinstock lecture at the International House at 4:10pm on March 21, 2017. Join us for her lecture "Food Politics and the Twenty-First Century Food Movement."
MCB Professor and Co-Chair, Nipam Patel, and his lab share insights into how butterfly wings develop. Watch this new video, created by the California Academy of Sciences, posted on its bioGraphic website:
In 2016-2017, UC Berkeley's Bakar Fellows Program is supporting the cutting edge research of two MCB faculty members -- Professor Kathy Collins and Professor Jim Hurley. Read more about their exciting and entrepreneurial work:
Aiding Cells’ Strategy to Survive (Hurley's work)
Trading in the Scalpel for a Sharper Blade (Collins' work)
"The Patent Trial and Appeal Board ruled that the inventions claimed in the pending U.S. patent application filed by the Doudna/Charpentier research group and the patents and applications filed by the Broad Institute are separately patentable from one another, thereby moving the Doudna/Charpentier group’s application closer to issuance as a U.S. patent."
The lab of MCB & Chemistry Professor and HHMI Investigator Chris Chang has developed a new way to transport chemicals throughout the body by bioconjugating them to amino acids through a process known as redox activated chemical tagging, or ReACT. The invention has been called “a chemical swiss army knife” by Chang due to its wide range of potential applications, from drug delivery systems to water purification processes.
MCB Affiliated Professor Dan Fletcher (who is Chair of the Department of Bioengineering) was one of the thirteen UC Berkeley faculty that were named Chan Zuckerberg Biohub Investigators. Fletcher "will launch a new effort to map the topography and spatial organization of cell-cell surfaces, starting with macrophages in their interactions with tumor cells."
The MCB Department is fully committed to supporting, in every way possible, all members of our department, irrespective of their national origin, religious background, race, color, age, sex, gender, gender identity, or sexual orientation. We are particularly troubled by the recent Executive Order on Immigration because it threatens members of our community and the practice of science. MCB scientists and staff come from many countries and engage in numerous international collaborations. Our research is enhanced by the diversity of perspectives provided by scientists from different backgrounds including international scientists. In addition, everyone’s science benefits when all scientists can travel freely between the U.S. and other countries to communicate directly with each other. We will resist policies that threaten our scientific culture and values.
"Jennifer Doudna and Emmanuelle Charpentier were awarded the Japan Prize today for their invention of the revolutionary gene-editing technology known as CRISPR-Cas9, which has swept into research labs around the world and is already yielding new therapies for cancer and hereditary diseases."
UC Berkeley researchers studying cancer and infectious disease are joining forces in an attempt to maniupulate the immune response for both invaders through immunotherapy. The recently formed IVRI, Immunotherapeutics and Vaccine Research Institute, is at the forefront of this collaborative work.